Meteora Capital’s EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share EQHA.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-275,690
Closed -$23K 522
2022
Q3
$23K Hold
275,690
0.01% 239
2022
Q2
$26K Buy
+275,690
New +$57K ﹤0.01% 329

Other funds holding EQHA.WS

Meteora Capital's EQHA.WS Position: Q4 2022 in Review

Meteora Capital sold out of EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share (EQHA.WS) in Q4 2022, closing a stake of 275,690 shares — an estimated $23K sold.

Meteora Capital first reported a position in EQHA.WS in Q2 2022 and held it in 2 quarters. The position peaked at $26K in Q2 2022. 1 fund tracked by Wall St. Rank holds EQHA.WS as of Q4 2022.

  • Meteora Capital reported no remaining EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share position as of Q4 2022 after selling out during the quarter.
  • Meteora Capital sold 275,690 EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share shares in Q4 2022, an estimated $23K.
  • Meteora Capital first reported a position in EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share in Q2 2022 and held it in 2 quarters.
  • Meteora Capital's EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share position peaked at $26K in Q2 2022.
  • 1 fund tracked by Wall St. Rank held EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share as of Q4 2022.

Based on Meteora Capital's 13F filing for Q4 2022, filed 14 Feb 2023.